A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor
to limit the dosage and the continuation of chemotherapy. A newly pegylated rhG-CSF was
independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China. Phase 1a, 1b and phase 2
trials have shown that pegylated rhG-CSF has decreased renal clearance, increased plasma
half-life, and prolonged efficacy in compare with rhG-CSF. The purpose of this study is to
determine the safety and effectiveness of pegylated rhG-CSF in preventing neutropenia
following chemotherapy in patients with breast cancer.